Sodium Oligomannate: First Approval
- PMID: 32020555
- DOI: 10.1007/s40265-020-01268-1
Sodium Oligomannate: First Approval
Erratum in
-
Correction to: Sodium Oligomannate: First Approval.Drugs. 2020 Mar;80(4):445-446. doi: 10.1007/s40265-020-01274-3. Drugs. 2020. PMID: 32096019
Abstract
Sodium oligomannate (®; GV-971) is a marine algae-derived oral oligosaccharide being developed by Shanghai Green Valley Pharmaceuticals for the treatment of Alzheimer's disease (AD). Sodium oligomannate received its first approval in November 2019 in China for the treatment of mild to moderate AD to improve cognitive function. This article summarizes the milestones in the development of sodium oligomannate leading to this first approval for AD.
References
-
- Acta Pharmacol Sin. 2013 Dec;34(12):1585-91 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
